Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
Full Year Results 2024
Watch Riad Mishlawi, CEO
Latest stories
Featured
Hikma to host meet the management and site visit in Columbus, Ohio
Press Release, Corporate 17 March 2025
- Hikma to host meet the management and site visit in Columbus, Ohio Press Release, Corporate 17 March 2025 Hikma to host meet the management and site visit in Columbus, Ohio
- Hikma receives FDA approval and launches Mercaptopurine Oral Suspension in the US Press Release, Product 27 February 2025 Hikma receives FDA approval and launches Mercaptopurine Oral Suspension in the US
- Strong 2024 performance and a positive outlook for 2025 Press Release, Financial Results 26 February 2025 Strong 2024 performance and a positive outlook for 2025
- Notice of results Press Release, Financial Results 10 February 2025 Notice of results
